NCT07207408招募中2 期
Phase 2, Randomized, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 148
- 试验地点
- 7
- 主要终点
- Anti-rF1V antibody level
研究概览
简要总结
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
详细描述
This dose-finding study will evaluate the immunogenicity, safety, and tolerability of multiple doses and regimens of rF1V-1018 vaccine in healthy adults. Immunogenicity blood samples will be drawn at several timepoints during the study. Participants will return to the clinic for periodic visits for study specific evaluations including evaluation of immunogenicity and safety. Safety assessments will be done at regular intervals through the end of the trial.
Six dose regimens will be tested in Part 1 of the study. Up to two dose regimens from Part 1 will be chosen for Part 2 of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
The study is partially blinded which means observers and participants know what study vaccine is being administered for some treatment arms but not for other treatment arms.
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults 18 to 55 years of age
- •Healthy participants or participants with stable pre-existing medical conditions Pre-existing stable medical condition means a participant who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.
- •Able to comply with the protocol schedule and procedures
- •Able and willing to provide written informed consent
- •If female of child-bearing potential and heterosexually active, has practiced adequate contraception for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through three months following the final trial injection
- •A premenopausal woman who has at least one of the following is considered not of childbearing potential:
- •Documented hysterectomy
- •Documented bilateral salpingectomy
- •Documented bilateral oophorectomy
- •Documented and current bilateral tubal ligation or occlusion
排除标准
- •A history of plague disease or have previously received any plague vaccine
- •Active tuberculosis or other systemic infectious process
- •History of human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
- •History of autoimmune disorder
- •History of sensitivity to any component of trial vaccines
- •Body mass index ≥ 30 kg/m2
- •Has received the following prior to any trial injection:
- •a) ≤ 14 days: i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG) b) ≤ 28 days: i) Any live vaccine ii) Any investigational medicinal agent c) ≤ 90 days: i) Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first trial vaccine administration or planned administration during the trial period. (For corticosteroids, this will mean prednisone ≥20 mg/day, or equivalent). Inhaled, topical, and intraarticular steroids are allowed.
- •ii) Granulocyte or granulocyte-macrophage colony stimulating factor iii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by-case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor) iv) Antisense oligonucleotides v) Drugs/investigational agents with very long half-lives (defined as ≥ 60 days) (eg, radioactive iodine, amiodarone, liraglutide, nirsevimab, teplizumab, evinacumab, and obinutuzumab) vi) Infusion of blood products d) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells
- •If female is pregnant (known before or established at the time of screening), breastfeeding, or planning breastfeeding or a pregnancy
- •Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
- •History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- •Oral temperature ≥ 38°C (≥ 100.4°F) at the time of vaccine administration
- •History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD)
结局指标
主要结局
Anti-rF1V antibody level
时间窗: 4 weeks after final study vaccine
Evaluate safety of rF1V-1018
时间窗: injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
Evaluate adverse events
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)DengueNCT05710224Butantan Institute1,364
已完成
2 期
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.Colorectal Cancer MetastaticNCT05243862Treos Bio Limited18
已完成
2 期
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in AdultsCOVID-19, SARS CoV 2 InfectionNCT05605470Technovalia, Pty Ltd150
已完成
2 期
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected PatientsHIV InfectionsNCT00316589Bavarian Nordic581
已完成
2 期
Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)COVID-19NCT05084989Jiangsu Rec-Biotechnology Co., Ltd.948